Efficacy and Safety of Fruquintinib Plus PD-1 Inhibitors Versus Regorafenib Plus PD-1 Inhibitors in Refractory Microsatellite Stable Metastatic Colorectal CancerLi‐Ying Sun, Jianbing Wu|Frontiers in Oncology|2021Cited by 39
Toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma (HEPATORCH): a randomised, open-label, phase 3 trialYing–Hong Shi, Enxiao Li, Weidong Jia et al.|The Lancet. Gastroenterology & hepatology|2025Cited by 39